| Similar Articles |
 |
The Motley Fool December 16, 2004 Nathan Slaughter |
Rx: Get Some Earnings Quick The No. 3 drug chain Rite Aid posts a sharp drop in earnings and slashes guidance again.  |
The Motley Fool January 13, 2004 Alyce Lomax |
CVS Fever Drug stores benefit from the flu bug, but for how much longer?  |
The Motley Fool July 5, 2005 Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.  |
The Motley Fool May 8, 2007 Ryan Fuhrmann |
CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.  |
The Motley Fool June 2, 2004 Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?  |
The Motley Fool November 10, 2004 Dave Marino-Nachison |
Investors Adjusting to Larger CVS The drugstore company's chains have done nothing but rise since the Eckerd buy. Investors have pulled the company's shares steadily upward since the merger closed.  |
The Motley Fool March 5, 2004 Dave Marino-Nachison |
Longs Coming Up Short Investors who bid on a Longs buyout haven't been rewarded in recent months.  |
The Motley Fool June 10, 2004 Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.  |
The Motley Fool February 2, 2005 Alyce Lomax |
CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.  |
The Motley Fool January 8, 2007 Matthew Crews |
CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note.  |
The Motley Fool January 3, 2005 Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.  |
The Motley Fool July 6, 2007 Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers.  |
The Motley Fool May 9, 2005 Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.  |
The Motley Fool January 5, 2004 Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.  |
The Motley Fool April 9, 2007 Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.  |
The Motley Fool February 12, 2004 Dave Marino-Nachison |
CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January.  |
The Motley Fool June 11, 2007 Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.  |
The Motley Fool March 9, 2004 Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.  |
The Motley Fool March 22, 2004 Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.  |
The Motley Fool July 6, 2004 Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.  |
The Motley Fool August 8, 2005 Mike Cianciolo |
A Cautiously Optimistic CVS The retail pharmacy nudges guidance up after an impressive quarter. All things considered, the outlook seems bright for investors in this company.  |
The Motley Fool August 15, 2005 Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.  |
The Motley Fool September 14, 2006 Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.  |
The Motley Fool March 9, 2005 Steven Mallas |
CVS Comps Feast on Flu CVS enjoys a nice jump in same-store sales for the month of February -- thanks, in part, to colds and the flu.  |
The Motley Fool November 9, 2005 Steven Mallas |
CVS Needs Rx for Cash The drugstore chain has the prescription for earnings growth, but investors need to keep an eye on free cash flow.  |
The Motley Fool March 28, 2005 Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?  |
The Motley Fool September 27, 2005 Nathan Slaughter |
All Green for Walgreen The retail pharmacy posts record earnings and sales for the 31st consecutive year. Even though Walgreen's latest numbers came up a little short of the mark, it wasn't enough to capture the attention of value investors.  |
The Motley Fool September 22, 2005 Stephen D. Simpson |
Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had.  |
The Motley Fool August 31, 2011 Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.  |
The Motley Fool October 21, 2004 Nathan Slaughter |
Outback's Earnings Served Cold The steak house has more to offer diners than investors.  |
The Motley Fool October 5, 2004 Nathan Slaughter |
Less of a Shine on Ruby Tuesday The restaurant chain meets Q1 earnings, but lowers guidance for fiscal 2005.  |
The Motley Fool March 6, 2008 Timothy M. Otte |
Longs Drugs Has a Nice Niche West Coast regional drugstore chain scores solid fourth quarter.  |
The Motley Fool June 26, 2007 Ryan Fuhrmann |
Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.  |
The Motley Fool January 4, 2008 Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.  |
The Motley Fool August 1, 2007 Ryan Fuhrmann |
Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one.  |
The Motley Fool May 5, 2004 Mike Cianciolo |
CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways.  |
The Motley Fool November 2, 2006 Ryan Fuhrmann |
CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note.  |
The Motley Fool September 26, 2006 Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?  |
The Motley Fool January 5, 2007 Matthew Crews |
Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve.  |
The Motley Fool September 22, 2006 Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.  |
The Motley Fool June 18, 2007 Rich Duprey |
Foolish Forecast: Walgreens Prescribes Growth The drugstore and convenience shop chain will report its third-quarter 2007 financial results shortly. Investors, here is what you can expect to see.  |
The Motley Fool June 29, 2006 Ryan Fuhrmann |
Walgreen's Prescription for Growth The drugstore chain continues to roll, even if it is a bit pricey. Great companies rarely trade at bargain-basement levels. But if savvy investors keep a watchful eye, they may find an opportunity to pick up some shares at a fairer price.  |
The Motley Fool December 11, 2006 Matthew Crews |
Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.  |
The Motley Fool February 4, 2005 Steven Mallas |
Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it.  |
The Motley Fool February 16, 2005 Brian Gorman |
Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies?  |
The Motley Fool June 28, 2005 Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.  |
The Motley Fool July 6, 2004 Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.  |
The Motley Fool September 29, 2010 Andrew Bond |
Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters.  |
The Motley Fool September 7, 2004 Seth Jayson |
Rejecting Rite Aid Shares of the drugstore chain droped 13%, and may prove to be a bargain if this is indeed a temporary slowdown and management can deliver more robust growth.  |
The Motley Fool January 4, 2005 Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.  |